published meta-analysis   sensitivity analysis   studies

convalescent plasma treatment in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias 14-days deathsdetailed resultsConPlas-19, 2020 0.56 [0.20; 1.57] DAWN-Plasma, 2021 0.61 [0.24; 1.55] NCT04397757, 2021 0.47 [0.04; 5.45] Sekine (PLACOVID), 2021 2.14 [0.70; 6.58] 0.82[0.42; 1.61]ConPlas-19, 2020, DAWN-Plasma, 2021, NCT04397757, 2021, Sekine (PLACOVID), 2021424%1,072moderatenot evaluable death D28detailed resultsAlQahtani, 2020 0.47 [0.04; 5.69] ASCOT, 2021 0.60 [0.06; 5.99] Bennett-Guerrero, 2021 0.86 [0.24; 3.11] Co-CLARITY, 2021 0.92 [0.02; 50.28] CONCOR-1, 2021 1.12 [0.86; 1.46] ConPlas-19, 2020 0.49 [0.20; 1.19] CONTAIN COVID-19, 2021 0.86 [0.60; 1.25] COPLA-II trial, 2020 1.17 [0.72; 1.92] DAWN-Plasma, 2021 0.99 [0.52; 1.88] Kirenga, 2021 1.25 [0.46; 3.39] Li, 2020 0.59 [0.22; 1.59] LIFESAVER, 2021 2.00 [0.16; 24.66] Menichetti, 2021 0.75 [0.37; 1.53] NCT04397757, 2021 0.15 [0.03; 0.75] NCT04403477 (two doses), 2021 0.53 [0.14; 2.01] NCT04528368, 2021 0.88 [0.02; 50.20] O’Donnell, 2021 0.47 [0.21; 1.06] PC/COVID-19, 2021 0.63 [0.11; 3.58] PERUCONPLASMA, 2021 0.36 [0.04; 3.13] PlasmAr, 2020 0.93 [0.47; 1.85] Pouladzadeh, 2021 0.31 [0.01; 10.20] RECOVER, 2021 1.09 [0.38; 3.13] RECOVERY (plasma), 2021 1.00 [0.93; 1.07] Sekine (PLACOVID), 2021 1.38 [0.73; 2.62] 0.99[0.93; 1.05]AlQahtani, 2020, ASCOT, 2021, Bennett-Guerrero, 2021, Co-CLARITY, 2021, CONCOR-1, 2021, ConPlas-19, 2020, CONTAIN COVID-19, 2021, COPLA-II trial, 2020, DAWN-Plasma, 2021, Kirenga, 2021, Li, 2020, LIFESAVER, 2021, Menichetti, 2021, NCT04397757, 2021, NCT04403477 (two doses), 2021, NCT04528368, 2021, O’Donnell, 2021, PC/COVID-19, 2021, PERUCONPLASMA, 2021, PlasmAr, 2020, Pouladzadeh, 2021, RECOVER, 2021, RECOVERY (plasma), 2021, Sekine (PLACOVID), 2021240%16,666moderatecritical deathsdetailed resultsAlQahtani, 2020 0.47 [0.04; 5.69] ASCOT, 2021 0.60 [0.06; 5.99] Baldeon, 2022 1.85 [0.49; 6.97] Bennett-Guerrero, 2021 0.80 [0.26; 2.45] CAPSID, 2021 0.84 [0.28; 2.50] CCAP-2, 2021 2.03 [0.61; 6.77] Co-CLARITY, 2021 0.92 [0.02; 50.28] CONCOR-1, 2021 1.02 [0.77; 1.36] ConCOVID (Gharbharan et al.), 2020 0.95 [0.20; 4.59] CONFIDENT, 2020 0.84 [0.52; 1.37] ConPlas-19, 2020 0.46 [0.19; 1.15] CONTAIN COVID-19, 2021 0.86 [0.60; 1.25] COP-COVID-19, 2021 0.96 [0.36; 2.56] COPLA-II trial, 2020 1.17 [0.72; 1.92] CP-COVID-19, 2021 3.20 [0.62; 16.39] DAWN-Plasma, 2021 0.99 [0.52; 1.88] Holm K, 2021 0.49 [0.08; 2.89] Kirenga, 2021 1.25 [0.46; 3.39] Li, 2020 0.59 [0.22; 1.59] Libster, 2020 0.50 [0.09; 2.71] LIFESAVER, 2021 2.00 [0.16; 24.66] Menichetti, 2021 0.75 [0.37; 1.53] NCT04385199, 2021 0.75 [0.15; 3.77] NCT04397757, 2021 0.15 [0.03; 0.75] NCT04403477 (two doses), 2021 0.53 [0.14; 2.01] NCT04442191, 2021 0.11 [0.00; 143.68] NCT04528368, 2021 0.88 [0.02; 50.20] O’Donnell, 2021 0.47 [0.21; 1.06] PC/COVID-19, 2021 0.63 [0.11; 3.58] PERUCONPLASMA, 2021 0.36 [0.04; 3.13] PlasmAr, 2020 0.93 [0.47; 1.85] Pouladzadeh, 2021 0.31 [0.01; 10.20] Rasheed, 2020 0.13 [0.01; 1.09] RECOVER, 2021 1.09 [0.38; 3.13] RECOVERY (plasma), 2021 1.00 [0.93; 1.07] REMAP-CAP (plasma), 2021 0.96 [0.80; 1.15] Sekine (PLACOVID), 2021 1.38 [0.73; 2.62] 0.98[0.92; 1.04]AlQahtani, 2020, ASCOT, 2021, Baldeon, 2022, Bennett-Guerrero, 2021, CAPSID, 2021, CCAP-2, 2021, Co-CLARITY, 2021, CONCOR-1, 2021, ConCOVID (Gharbharan et al.), 2020, CONFIDENT, 2020, ConPlas-19, 2020, CONTAIN COVID-19, 2021, COP-COVID-19, 2021, COPLA-II trial, 2020, CP-COVID-19, 2021, DAWN-Plasma, 2021, Holm K, 2021, Kirenga, 2021, Li, 2020, Libster, 2020, LIFESAVER, 2021, Menichetti, 2021, NCT04385199, 2021, NCT04397757, 2021, NCT04403477 (two doses), 2021, NCT04442191, 2021, NCT04528368, 2021, O’Donnell, 2021, PC/COVID-19, 2021, PERUCONPLASMA, 2021, PlasmAr, 2020, Pouladzadeh, 2021, Rasheed, 2020, RECOVER, 2021, RECOVERY (plasma), 2021, REMAP-CAP (plasma), 2021, Sekine (PLACOVID), 2021370%19,874moderatecritical deaths (time to event analysis only)detailed resultsBaldeon, 2022 1.85 [0.49; 6.97] Bennett-Guerrero, 2021 0.80 [0.26; 2.45] CONCOR-1, 2021 1.02 [0.77; 1.36] ConPlas-19, 2020 0.46 [0.19; 1.15] CP-COVID-19, 2021 3.20 [0.62; 16.39] DAWN-Plasma, 2021 0.99 [0.52; 1.88] PlasmAr, 2020 0.93 [0.47; 1.85] 0.99[0.79; 1.24]Baldeon, 2022, Bennett-Guerrero, 2021, CONCOR-1, 2021, ConPlas-19, 2020, CP-COVID-19, 2021, DAWN-Plasma, 2021, PlasmAr, 202070%2,439moderatenot evaluable clinical deteriorationdetailed resultsCAPSID, 2021 0.63 [0.29; 1.40] ConPlas-19, 2020 1.00 [0.65; 1.53] CONTAIN COVID-19, 2021 0.94 [0.75; 1.18] Kirenga, 2021 0.91 [0.38; 2.17] Libster, 2020 0.52 [0.29; 0.94] 0.87[0.71; 1.06]CAPSID, 2021, ConPlas-19, 2020, CONTAIN COVID-19, 2021, Kirenga, 2021, Libster, 202059%1,357moderatenot evaluable clinical improvementdetailed resultsBennett-Guerrero, 2021 0.75 [0.21; 2.68] CAPSID, 2021 1.58 [0.71; 3.49] ConPlas-19, 2020 0.95 [0.60; 1.52] Li, 2020 1.40 [0.79; 2.49] O’Donnell, 2021 1.20 [0.87; 1.65] PlasmAr, 2020 0.81 [0.50; 1.31] Pouladzadeh, 2021 7.31 [1.62; 32.97] Sekine (PLACOVID), 2021 0.94 [0.74; 1.19] 1.09[0.87; 1.38]Bennett-Guerrero, 2021, CAPSID, 2021, ConPlas-19, 2020, Li, 2020, O’Donnell, 2021, PlasmAr, 2020, Pouladzadeh, 2021, Sekine (PLACOVID), 2021839%1,139moderatenot evaluable clinical improvement (14-day)detailed resultsLi, 2020 2.27 [0.90; 5.72] 2.27[0.90; 5.72]Li, 202010%103NAnot evaluable clinical improvement (28-day)detailed resultsBennett-Guerrero, 2021 1.02 [0.25; 4.20] Li, 2020 1.42 [0.65; 3.10] O’Donnell, 2021 1.38 [0.73; 2.61] Pouladzadeh, 2021 7.31 [1.62; 32.97] Sekine (PLACOVID), 2021 0.94 [0.74; 1.19] 1.33[0.83; 2.14]Bennett-Guerrero, 2021, Li, 2020, O’Donnell, 2021, Pouladzadeh, 2021, Sekine (PLACOVID), 2021553%620moderatenot evaluable clinical improvement (7-day)detailed resultsLi, 2020 0.98 [0.27; 3.58] 0.98[0.27; 3.58]Li, 202010%103NAnot evaluable clinical improvement (time to event analysis only)detailed resultsBennett-Guerrero, 2021 0.75 [0.21; 2.68] ConPlas-19, 2020 0.95 [0.60; 1.52] Li, 2020 1.40 [0.79; 2.49] O’Donnell, 2021 1.20 [0.87; 1.65] PlasmAr, 2020 1.00 [0.76; 1.32] 1.08[0.90; 1.29]Bennett-Guerrero, 2021, ConPlas-19, 2020, Li, 2020, O’Donnell, 2021, PlasmAr, 202050%815lownot evaluable death or ventilationdetailed resultsCONCOR-1, 2021 1.16 [0.94; 1.43] ConPlas-19, 2020 0.94 [0.86; 1.02] DAWN-Plasma, 2021 1.01 [0.64; 1.59] Menichetti, 2021 0.88 [0.59; 1.32] RECOVERY (plasma), 2021 0.99 [0.93; 1.05] 0.98[0.94; 1.03]CONCOR-1, 2021, ConPlas-19, 2020, DAWN-Plasma, 2021, Menichetti, 2021, RECOVERY (plasma), 202150%13,182moderatenot evaluable hospital dischargedetailed resultsConPlas-19, 2020 1.02 [0.82; 1.28] DAWN-Plasma, 2021 1.06 [0.87; 1.30] RECOVERY (plasma), 2021 0.99 [0.92; 1.07] 1.00[0.94; 1.07]ConPlas-19, 2020, DAWN-Plasma, 2021, RECOVERY (plasma), 202130%12,391moderatenot evaluable mechanical ventilationdetailed resultsAlQahtani, 2020 0.67 [0.22; 2.02] COPLA-II trial, 2020 0.58 [0.37; 0.92] Holm K, 2021 0.39 [0.01; 12.68] NCT04397757, 2021 0.41 [0.13; 1.35] O’Donnell, 2021 1.50 [0.47; 4.82] PlasmAr, 2020 0.86 [0.39; 1.93] RECOVERY (plasma), 2021 0.98 [0.88; 1.09] 0.83[0.64; 1.08]AlQahtani, 2020, COPLA-II trial, 2020, Holm K, 2021, NCT04397757, 2021, O’Donnell, 2021, PlasmAr, 2020, RECOVERY (plasma), 2021724%12,047moderatenot evaluable mechanical ventilation (time to event analysis only)detailed resultsCP-COVID-19, 2021 0.66 [0.25; 1.72] DAWN-Plasma, 2021 1.08 [0.65; 1.80] 0.97[0.62; 1.52]CP-COVID-19, 2021, DAWN-Plasma, 202120%583moderatenot evaluable viral clearance detailed resultsCP-COVID-19, 2021 1.12 [0.16; 7.84] Salman, 2020 1.00 [0.02; 53.89] 1.10[0.19; 6.30]CP-COVID-19, 2021, Salman, 202020%130moderatenot evaluable viral clearance by day 14detailed resultsCP-COVID-19, 2021 1.51 [0.33; 6.94] Kirenga, 2021 0.95 [0.76; 1.19] 0.96[0.77; 1.20]CP-COVID-19, 2021, Kirenga, 202120%225moderatenot evaluable viral clearance by day 7detailed resultsKirenga, 2021 0.87 [0.65; 1.16] Salman, 2020 1.00 [0.02; 53.89] 0.87[0.65; 1.16]Kirenga, 2021, Salman, 202020%158moderatenot evaluable ICU admissiondetailed resultsCP-COVID-19, 2021 0.82 [0.35; 1.91] Libster, 2020 0.33 [0.07; 1.58] 0.67[0.32; 1.41]CP-COVID-19, 2021, Libster, 202021%260moderatenot evaluable serious adverse eventsdetailed resultsCONCOR-1, 2021 1.27 [1.02; 1.58] ConPlas-19, 2020 0.89 [0.43; 1.86] O’Donnell, 2021 0.64 [0.35; 1.17] PlasmAr, 2020 1.40 [0.78; 2.51] REMAP-CAP (plasma), 2021 2.28 [1.17; 4.46] Sekine (PLACOVID), 2021 1.14 [0.88; 1.48] 1.19[0.94; 1.50]CONCOR-1, 2021, ConPlas-19, 2020, O’Donnell, 2021, PlasmAr, 2020, REMAP-CAP (plasma), 2021, Sekine (PLACOVID), 2021645%3,964moderatenot evaluable adverse eventsdetailed resultsKirenga, 2021 1.13 [0.50; 2.58] Sekine (PLACOVID), 2021 1.08 [0.85; 1.38] 1.08[0.86; 1.37]Kirenga, 2021, Sekine (PLACOVID), 202120%296moderatenot evaluable0.55.01.0relative treatment effectwww.metaEvidence.org2024-03-29 02:46 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 538,957 - roots T: 290